Abstract
In view of the shortcomings of the current system for postmarketing drug surveillance that is based on voluntary spontaneous adverse drug reaction (ADR) reporting, new approaches are needed.
We describe an approach involving a combination of limited distribution, patient and physician education, as well as a novel pharmacovigilance system that is capable of promoting the safe and adequate use of a new drug. Importantly, it provides the possibility of calculating true ADR occurrence rates, as the exposed population (denominator) and the number of patients with events (numerator) are known. These measures were taken for the oral dual endothelin ETA/ETB antagonist bosentan (Tracleer®). In recent guidelines issued by the European Society of Cardiology, American College of Chest Physicians and the WHO, this drug is considered as first-line oral treatment for the treatment of pulmonary arterial hypertension, a devastating orphan disease associated with a poor prognosis. Bosentan was approved in 2001/2 on the basis of two pivotal studies that showed improved exercise capacity and haemodynamic parameters while delaying time to clinical worsening. Elevations in serum liver aminotransferase levels of >3 times the upper limit of normal were noted in 10.2% of patients (placebo-subtracted incidence). Therefore, liver function tests have to be performed on a regular basis. In addition, bosentan has potential as a teratogen.
In the US, a controlled distribution network for bosentan (Tracleer® Access Program [T.A.P.]) and the development of a patient database to follow patients was set up. Accompanied by comprehensive physician and patient education programmes, T.A.P. was developed to provide a mechanism to assist with the primary risk management goals for bosentan therapy, namely pregnancy prevention and liver enzyme monitoring and prevention of hepatic injury.
In Europe, the Tracleer® Excellence (TRAX PMS) database is a novel European non-interventional, prospective, internet-based surveillance system initiated by the manufacturer in cooperation with the European Medicines Agency. It collected potential safety signals associated with bosentan use including adverse events, elevations of liver aminotransferase levels, other abnormal laboratory values, death and hospitalisation. TRAX PMS has accrued 79% of all known patients in the EU and the data provide supportive ‘real-life’ evidence on the long-term safety of bosentan.
The two different systems had similar goals and outcomes. The data received concerning thousands of patient-years of use have confirmed the clinical trial results regarding product safety and the favourable benefit/risk ratio of bosentan, especially with regard to known type A adverse events. The clinical monitoring algorithm has also been confirmed. In addition, no rare type B events were uncovered despite the increased reporting rate. These systems might serve as templates for future pharmacovigilance efforts regarding drugs that require particular safety attention.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Strom BL. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint. JAMA 2004; 292(21): 2643–6
Fontanarosa PB, Rennie D, DeAngelis CD. Postmarketing surveillance: lack of vigilance, lack of trust. JAMA 2004; 292(21): 2647–50
Centers for Education and Research on Therapeutics (CERTs) Risk Assessment Workshop Participants. Risk assessment of drugs, biologics and therapeutic devices: present and future issues. Pharmacoepidemiol Drug Saf 2003; 12 (8): 653-62
Strom BL, Tugwell P. Pharmacoepidemiology: current status, prospects, and problems. Ann Intern Med 1990; 113: 179–81
Rawlins MD. Pharmacovigilance: paradise lost, regained or postponed? The William Withering Lecture 1994. J R Coll Physicians Lond 1995; 29: 41–9
Food and Drug Administration (FDA) Working Group. PhRMA/FDA/AASLD drug-induced hepatotoxicity white paper: postmarketing considerations, November 2000 [online]. Available from URL: http://www.fda.gov/cder/livertox/postmarket.pdf [Accessed 2005 Mar 4]
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425–36
Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336(2): 111–7
Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004; 25(24): 2243–78
Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12 Suppl. S): 62S–7S
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346(12): 896–903
Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension; a randomised placebo-controlled study. Lancet 2001; 358(9288): 1119–23
Actelion Pharmaceuticals US, Inc. Tracleer® product information [online]. Available from URL: http://www.tracleer.com/TRALibrary/TRALib004/TRALib004PrescribingInfo.html [Accessed 2005 Sep 28]
Actelion Pharmaceuticals UK. Tracleer® EU summary of product characteristics, 2004 [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=10231 [Accessed 2005 Sep 28]
D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115(5): 343–9
McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25(2): 244–9
5th PSUR Tracleer®. Allschwil: Actelion Pharmaceuticals Ltd, 2005 Jan
7th TRAX PMS data report to CHMP for the cumulative period from 24 May 2002 to 19 November 2004. Allschwil: Actelion Pharmaceuticals Ltd, 2005 Feb 1. (Data on file)
Zimmerman H. Drug-induced liver disease. Clin Liver Dis 2000; 4(1): 73–96
Zimmerman H. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999
Food and Drug Administration (FDA) Working Group. CDER-PhRMA-AASLD Conference 2000: clinical white paper. Food and Drug Administration, Rockville, USA [online]. Available from URL: http://www.fda.gov/cder/livertox/clinical.pdf [Accessed 2005 Sep 12]
Acknowledgements
The authors are employees of Actelion Pharmaceuticals Ltd., the manufacturer of bosentan and sponsor of the systems described in this article.
The input of D. Pittrow, MD, PhD, Institute for Clinical Pharmacology, Technical University of Dresden to various sections of the manuscript is appreciated. We also acknowledge the input of Ralph Stadler, Senior Consultant, IBR AG to the TRAX system.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Segal, E.S., Valette, C., Oster, L. et al. Risk Management Strategies in the Postmarketing Period. Drug-Safety 28, 971–980 (2005). https://doi.org/10.2165/00002018-200528110-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-200528110-00001